key: cord-0808697-9pp81nw7
authors: Jevnikar, Mitja; Sanchez, Olivier; Chocron, Richard; Andronikof, Marc; Raphael, Maurice; Meyrignac, Olivier; Fournier, Laure; Montani, David; Planquette, Benjamin; Soudani, Mary; Boucly, Athénaïs; Pichon, Jeremie; Preda, Mariana; Beurnier, Antoine; Bulifon, Sophie; Seferian, Andrei; Jaïs, Xavier; Sitbon, Olivier; Savale, Laurent; Humbert, Marc; Parent, Florence
title: Prevalence of pulmonary embolism in patients with COVID 19 at the time of hospital admission
date: 2021-03-11
journal: Eur Respir J
DOI: 10.1183/13993003.00116-2021
sha: 581564037668910c81e282ce2073a39475aa60e2
doc_id: 808697
cord_uid: 9pp81nw7

A high prevalence of venous thromboembolism (VTE) has been reported during Intensive Care Unit (ICU) hospitalisation in patients with severe coronavirus disease (COVID-19) [1, 2]. In most cases, the diagnosis of pulmonary embolism (PE) was incidental as patients underwent computed tomography pulmonary angiography (CTPA) for aggravation of their respiratory condition. Higher mortality is also described in patients with high D-Dimer levels suggesting that VTE complication may contribute to unfavourable prognosis [3, 4]. Even though, prevalence of thromboembolic complications during ICU hospitalisation seems to be high, the prevalence of PE at hospital admission for COVID-19 is unknown and may be underestimated.

A high prevalence of venous thromboembolism (VTE) has been reported during Intensive Care Unit (ICU) hospitalisation in patients with severe coronavirus disease (COVID-19) 1, 2 . In most cases, the diagnosis of pulmonary embolism (PE) was incidental as patients underwent computed tomography pulmonary angiography (CTPA) for aggravation of their respiratory condition. Higher mortality is also described in patients with high D-Dimer levels suggesting that VTE complication may contribute to unfavourable prognosis 3, 4 . Even though, prevalence of thromboembolic complications during ICU hospitalisation seems to be high, the prevalence of PE at hospital admission for COVID-19 is unknown and may be underestimated.

In the present research letter, we report a prospective multicentre study that evaluates the PE prevalence in patients admitted for COVID-19, at the time of admission in three tertiary hospitals, Bicêtre Hospital and Béclère Hospital, University Paris-Saclay, and European Georges Pompidou Hospital, Paris University.

All consecutive adult outpatients hospitalized between April 15, 2020 to May 23, 2020 with a diagnosis of COVID-19 were included and underwent a CTPA, if not contraindicated, at the time of hospital admission. Patients with renal failure (<30mL/min of clearance) or contraindications to iodinated contrast material were excluded from the study. COVID-19 diagnosis was confirmed by the presence of positive SARS-CoV-2 RT-PCR and/or typical CT abnormalities (i.e ground-glass opacities and/or consolidation in the lung periphery) 5, 6 . Hospital admission was decided by the clinician in charge at the emergency department (ED) of each participating hospital according to clinical criteria.

The CT patterns of COVID-19 pneumonia and the presence of PE were analysed locally by a senior radiologist and a pulmonologist. Patients without PE received prophylactic anticoagulation during hospitalisation, according to local practice.

Patients were prospectively followed-up for three months or until death, by a telephone interview within 3 months after admission.

Performing systematic CTPA was in accordance with the multidisciplinary medical crisis team for COVID-19 and all patients received oral information about data collection. Upon consent, data were recorded in an anonymous database registered to the National Commission on Informatics and Liberty (n°26750045200441). The study was been approved by the CERAPHP Centre (Comité d'éthique de la recherche APHP Centre; IRB registration: #00011928).

Quantitative data are expressed as median (interquartile range, 25% to 75% [IQR]) and qualitative data are expressed as number of occurrences, n (%). The prevalence of PE was calculated, and the 95% confidence intervals (CI) were determined.

Comparisons between groups were performed using the independent student's t-test During the study period, 135 consecutives outpatients were hospitalised for COVID-19 at the three participating hospitals. Among them, 29 (21.5%) were excluded from the study, mainly due to contraindications for iodinated contrast administration (n=12), inability to understand oral information (n=7) and screening failure (n=10). Of the 106 included patients, 5 (4.7%) patients were directly admitted to an ICU.

Overall, PE was diagnosed in 15 of 106 patients giving a prevalence of 14.2% (95%CI 7.5-20.8). Among the 5 patients directly admitted in ICU, 1 had a confirmed PE at admission. Table 1 (Table 1) .

Hospital mortality in patients with confirmed PE on admission was 4/15 (26.6%) and

was not statistically different compared to hospital mortality of the group without PE 10/91 (11.0%) (p=0.09) which might be primarily driven by the small study size. At 3months, no patients were lost to follow-up and seven additional deaths occurred for a total mortality rate of 21/106 (19.8%). Of these 7 deaths, 6 were due to comorbidities and 1 was of unknown cause in an 85 year-old woman. No VTE recurrence occurred after hospital discharge in survivors.

This present study showed a prevalence of PE of 14.2%, (95%CI 7.5-20.8) at the time of hospital admission for COVID-19. In line with previous reports, our study suggests that PE is a common complication among COVID-19 patients 1,2 .However, this is the first study to describe the prevalence of PE at hospital admission.

Although a high prevalence of PE is reported in ICU (20.6-27%) and at conventional wards (8.3%) in patients with COVID-19, all these studies, the reported prevalence of PE is potentially biased since CTPA was only performed in COVID-19 patients with clinical aggravation and/or with clinical suspicion for PE and CTPA might not have been performed in intubated patients with a severe clinical course 1, [7] [8] [9] . In contrast, in our study, CTPA was performed routinely on admission regardless of whether PE was clinically suspected or not.

During follow up, no other Pes were diagnosed, suggesting that looking for PE at the time of admission, and using a prophylactic anticoagulant treatment in the absence of PE, is safe and prevents new PE during the in-hospital period and 3-month follow-up period.

One of the study limitations is the relatively small number of COVID-19 admitted patients. Indeed, our study started after the lockdown setting of our region that fortunately reduced the number of COVID-19 hospitalisation. Additionally, 21.5% of patients were excluded from the study, mostly due to contraindications to iodinated contrast injection or inability to understand verbal information about the study due to dementia. Lastly, there were protocol violations because D-dimer tests were not done in 8 patients, 2 of whom had acute PE confirmed on CTPA. Large multicentre cohort studies are needed to confirm these data and explore the reasons why SARS-CoV-2 predisposes to VTE events, as no other respiratory viruses are known to do this [10] [11] [12] [13] .

In conclusion, this prospective study reported a high prevalence of PE in patients with COVID-19 at time of hospital admission. For this reason, we support CTPA exams on hospital admission in COVID-19 patients requiring supplemental oxygen, having high D-dimer concentrations or long history of COVID-19 symptoms, if no contraindicated.

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. TH Open Companion

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

COVID-19 patients and the radiology department -advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI)

Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence

Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Endothelial cell infection and endotheliitis in COVID-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Pandemic H1N1 influenza infection and vascular thrombosis